News

Conference Coverage

Pemigatinib Yields Durable Responses, Prolonged Survival in FGFR2-Altered Cholangiocarcinoma

06/30/2022

Findings from the phase 2 FIGHT-202 trial reveal pemigatinib demonstrates durable response, prolonged overall survival, and manageable safety in patients with FGFR2-altered advanced of metastatic cholangiocarcinoma.

Findings from the phase 2...

06/30/2022

Oncology

News

Hepatic Arterial Infusion Pump Floxuridine Chemotherapy vs Resection for Intrahepatic Cholangiocarcinoma

05/19/2022

Amber Denham ;

Hepatic arterial infusion pump floxuridine chemotherapy yielded similar OS as resection in patients with multifocal intrahepatic cholangiocarcinoma and may be an effective alternative treatment option, according to a recent study.

Hepatic arterial infusion pump...

05/19/2022

Oncology

News

Genomic Profiling Suggests Combined Hepatocellular Cholangiocarcinoma Cases May Be Genomically Subclassified

03/01/2022

John Otrompke , BA, JD;

Study findings suggest that over 70% of combined hepatocellular cholangiocarcinoma cases may be genomically subclassified during treatment into disease which is more similar to hepatocellular carcinoma and cholangiocarcinoma.

Study findings suggest that over...

03/01/2022

Oncology

News

Association of KRAS Variant Subtypes With Survival, Recurrence in Surgically Treated Intrahepatic Cholangiocarcinoma

02/24/2022

Alexis Hyams ;

Study findings suggest the presence of G12 KRAS variants are associated with inferior survival and increased risk of recurrence in patients with intrahepatic cholangiocarcinoma.

Study findings suggest the...

02/24/2022

Oncology

News

Infigratinib Yields PFS, ORR Benefit in Patients With Cholangiocarcinoma and FGFR2 Fusions

07/01/2020

In a phase 2 trial, third- and later-line treatment with infigratinib led to a meaningful benefit in survival and response among patients with cholangiocarcinoma and FGFR2 fusions.

In a phase 2 trial, third- and...

07/01/2020

Oncology

News

FDA Approves Pemigatinib as First Therapy for Advanced Cholangiocarcinoma

04/20/2020

The FDA has approved pemigatinib for the treatment of adults with certain types of pretreated, advanced cholangiocarcinoma.

The FDA has approved pemigatinib...

04/20/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology